Buprenorphine: all 305 studies that test it
Page 3 of 4. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- A Study of Nopan Treatment of Acute SuicidalityStatus unknownNCT01046851Phase 3
- Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy AdultsCompletedNCT01046539Phase 1
- A Study Comparing Norspan Patch and Oral TramadolCompletedNCT01019265Phase 4
- Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted ConditionsCompletedNCT00992095Not applicable
- Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the FemurCompletedNCT00964808Phase 4
- Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")CompletedNCT00955162Phase 4
- Effects of Buprenorphine on Ulnar Nerve Motor BlockTerminatedNCT00949299Phase 4
- A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth PainTerminatedNCT00947466Phase 1/2
- Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic PainSuspendedNCT00916890Phase 4
- Multicentre Trial of Suboxone in Opiate-dependent Subjects in TaiwanCompletedNCT00901875Phase 4
- Comparison of Two Dosage Strengths of Transdermal Fentanyl Versus Transdermal Buprenorphine and Placebo in Acute Pain Models in Healthy Volunteers.CompletedNCT00886002Phase 1
- Interaction of Buprenorphine With HIV Medications and Tuberculosis MedicationsCompletedNCT00877591Phase 1
- A Double-Blind Study of Buprenorphine Treatment of Acute SuicidalityStatus unknownNCT00863291Phase 3
- Study of Probuphine in Patients With Opioid DependenceTerminatedNCT00772785Phase 3
- A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid DependenceTerminatedNCT00768482Phase 3
- Buprenorphine Naltrexone-P1 A-CocaineCompletedNCT00733720Phase 1
- Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus BuprenorphineCompletedNCT00679458Not applicable
- Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental PainCompletedNCT00647127Phase 3
- Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid DependenceCompletedNCT00630201Phase 3
- Sublingual Buprenorphine for Chronic PainStatus unknownNCT00612287Phase 2
- Buprenorphine for the Treatment of Neonatal Abstinence SyndromeCompletedNCT00521248Phase 1
- Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID 297307)TerminatedNCT00469404Phase 1
- Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID: 855509)TerminatedNCT00469053Phase 1
- Safety and Efficacy of Probuphine in the Treatment of Opioid DependenceCompletedNCT00447564Phase 3
- Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar SpineCompletedNCT00426647Phase 4
- HIV Risk Reduction and Drug Abuse Treatment in IranWithdrawnNCT00398008Phase 2
- Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch FormulationsTerminatedNCT00388219Phase 1
- Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-ReleaseCompletedNCT00367302Phase 1/2
- Pharmacokinetics and Pharmacodynamics of Buprenorphine in Healthy VolunteersStatus unknownNCT00347815Phase 1
- Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Low Back PainCompletedNCT00346047Phase 3
- Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic PainCompletedNCT00345787Phase 3
- The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.CompletedNCT00315887Phase 3
- The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.CompletedNCT00315874Phase 3
- The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.CompletedNCT00315848Phase 3
- Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.CompletedNCT00315835Phase 2
- Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.CompletedNCT00314652Phase 3
- Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.CompletedNCT00313833Phase 3
- Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)TerminatedNCT00279565Phase 4
- Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1CompletedNCT00249574Not applicable
- Buprenorphine as a Treatment for Individuals Dependent on Analgesic OpioidsCompletedNCT00218101Phase 2
- Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid UsersCompletedNCT00158236Not applicable
- Abuse Potential of Buprenorphine/NaloxoneTerminatedNCT00149539Phase 2
- Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid DependenceCompletedNCT00134914Not applicable
- Blockade Efficacy of Buprenorphine/Naloxone For Opioid DependenceCompletedNCT00134888Not applicable
- Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid AbusersTerminatedNCT00134875Not applicable
- Buprenorphine and Integrated HIV Care EvaluationStatus unknownNCT00124358Phase 4
- Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1CompletedNCT00078130Phase 3
- Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1CompletedNCT00078117Phase 3
- Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1CompletedNCT00032968Phase 3
- Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1CompletedNCT00032955Phase 3
- Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1CompletedNCT00023283Phase 2
- Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14CompletedNCT00015340Phase 4
- Buprenorphine and Naloxone Combination Study - 10CompletedNCT00015288Phase 1
- Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1CompletedNCT00015171Phase 3
- Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2CompletedNCT00015041Phase 1
- Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1CompletedNCT00015028Phase 2
- Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based PracticeCompletedNCT00007527Phase 4
- Buprenorphine Maintenance for Opiate Dependence - 6CompletedNCT00000357Phase 2
- Effects of Buprenorphine and Naloxone in Opiate Addicts - 4CompletedNCT00000355Phase 1
- Trial of Buprenorphine/Naloxone for Opiate Dependence - 2CompletedNCT00000353Phase 2
- Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9CompletedNCT00000344Phase 2
- Evaluation of Liquid vs. Tablet Buprenorphine - 6CompletedNCT00000341Phase 2
- Comparison of Buprenorphine and Methadone - 3CompletedNCT00000334Phase 2
- Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1CompletedNCT00000320Phase 1/2
- Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2CompletedNCT00000319Phase 2
- Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1CompletedNCT00000318Phase 2
- Combining Behavioral Treatment With Agonist Maintenance - 1CompletedNCT00000311Phase 3
- Study Comparing Liquid and Tablet Buprenorphine Formulations - 5CompletedNCT00000302Phase 3
- Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2CompletedNCT00000299Phase 2
- Buprenorphine Combination Tablet Feasibility - 1CompletedNCT00000298Phase 2
- Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on MethadoneTerminatedNCT00000243Not applicable
- Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22CompletedNCT00000240Phase 2
- Buprenorphine Pharmacology Related to Addiction Treatment - 21CompletedNCT00000239Phase 2
- Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20CompletedNCT00000238Phase 2
- Buprenorphine Detoxification - BBDVI - 19CompletedNCT00000237Phase 2
- Buprenorphine Pharmacology Related to Addiction Treatment - 18CompletedNCT00000236Phase 2
- Alternate Day Buprenorphine Administration, Phase XII - 17CompletedNCT00000235Phase 2
- Alternate Day Buprenorphine Administration, Phase XI - 16CompletedNCT00000234Phase 2
- Alternate Day Buprenorphine Administration, Phase X - 15CompletedNCT00000233Phase 2
- Alternate Day Buprenorphine Administration, Phase IX - 14CompletedNCT00000232Phase 2
- Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13CompletedNCT00000231Phase 2
- Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12CompletedNCT00000230Phase 2
- Buprenorphine Detox With Two Types of Treatment. BBD II - 11CompletedNCT00000229Phase 2
- Buprenorphine Detox With Two Types of Treatment. BBD I - 10CompletedNCT00000228Phase 2
- Alternate-Day Buprenorphine Administration. Phase VIII - 9CompletedNCT00000227Phase 2
- Alternate-Day Buprenorphine Administration. Phase VII - 8CompletedNCT00000226Phase 2
- Alternate-Day Buprenorphine Administration. Phase VI - 7CompletedNCT00000225Phase 2
- Alternate-Day Buprenorphine. Phase V - 6CompletedNCT00000224Phase 1
- Alternate-Day Buprenorphine Administration. Phase IV - 5CompletedNCT00000223Phase 2
- Alternate-Day Buprenorphine Administration. Phase II - 4CompletedNCT00000222Phase 1
- Alternate-Day Buprenorphine Administration. Phase I - 3CompletedNCT00000221Phase 1
- Gradual Vs. Rapid Buprenorphine Detoxification - 2CompletedNCT00000220Phase 1
- Buprenorphine Dose Alteration Study - 1CompletedNCT00000219Phase 1
- Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1CompletedNCT00000216Phase 3
- IV Cocaine Abuse: A Laboratory Model - 3CompletedNCT00000214Phase 2
- Treatment Efficacy for Drug Abuse and AIDS Prevention - 2CompletedNCT00000211Phase 2
- Treatment Efficacy for Drug Abuse and AIDS Prevention - 1CompletedNCT00000210Phase 2
- Buprenorphine Dosing Interval - 5CompletedNCT00000209Phase 2
- Methadone/Buprenorphine Cross-Over Study - 4CompletedNCT00000208Phase 2
- Multicenter Clinical Trial of Buprenorphine - 3CompletedNCT00000207Phase 3